BRAF and neoplasm: Median TTP (n=143) was longer in patients with RAS WT (13.2 (95% CI: 7.8, 17.0) months) vs MT tumours (7.3 (95% CI: 6.1, 7.6) months) and in those with RAS WT/BRAF WT (13.3 (95% CI: 9.0, 17.0) months) vs RAS or BRAF MT tumours (7.2 (95% CI: 5.7, 7.4) months).